Revolutionizing CAR-T Cell Therapy: The Future of Automation and Decentralization” ###

###
1. Decentralized Manufacturing: CAR-T manufacturers are exploring decentralized manufacturing to reduce costs and increase production speed. This approach involves moving production away from central facilities to multiple sites closer to customers.
2. Automation: Automation is seen as key to improving CAR-T cell therapy production, enhancing quality, and reducing costs. It can also foster innovation and reduce the workload for medical technicians.
3. Galapagos' Decentralized Approach: Galapagos is partnering with Blood Centers of America to establish a decentralized CAR-T manufacturing network across the US, aiming to reduce vein-to-vein time to just seven days.
4. Industry Advancements: The latest advancements in cell and gene therapy manufacturing, including novel production approaches and automation, are being discussed in industry forums and podcasts.
5. Global Expansion: Companies like Galapagos are looking to expand their decentralized manufacturing networks globally, including in Europe, Asia, Latin America, and the Middle East.